Loading…
Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone
Abstract STUDY QUESTION Does treatment of constitutional delay of growth and puberty (CDGP) in boys with aromatase inhibitor letrozole (Lz) or conventional low-dose testosterone (T) have differing effects on developing seminiferous epithelium? SUMMARY ANSWER Anti-Müllerian hormone (AMH) declined sim...
Saved in:
| Published in: | Human reproduction (Oxford) 2020-02, Vol.35 (2), p.257-264 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c420t-3497c9c07247cc962799f0367d15e8ad3b50c5ee6a75a4c36ccfa8def26f775d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c420t-3497c9c07247cc962799f0367d15e8ad3b50c5ee6a75a4c36ccfa8def26f775d3 |
| container_end_page | 264 |
| container_issue | 2 |
| container_start_page | 257 |
| container_title | Human reproduction (Oxford) |
| container_volume | 35 |
| creator | Kohva, E Varimo, T Huopio, H Tenhola, S Voutilainen, R Toppari, J Miettinen, P J Vaaralahti, K Viinamäki, J Backman, J T Hero, M Raivio, T |
| description | Abstract
STUDY QUESTION
Does treatment of constitutional delay of growth and puberty (CDGP) in boys with aromatase inhibitor letrozole (Lz) or conventional low-dose testosterone (T) have differing effects on developing seminiferous epithelium?
SUMMARY ANSWER
Anti-Müllerian hormone (AMH) declined similarly in both treatment groups, and the two Sertoli cell-derived markers (AMH and inhibin B (iB)) exhibited differing responses to changes in gonadotrophin milieu.
WHAT IS KNOWN ALREADY
Boys with CDGP may benefit from puberty-inducing medication. Peroral Lz activates gonadotrophin secretion, whereas intramuscular low-dose T may transiently suppress gonadotrophins and iB.
STUDY DESIGN, SIZE, DURATION
Sera of 28 boys with CDGP who participated in a randomised, controlled, open-label trial at four paediatric centres in Finland between August 2013 and January 2017 were analysed. The patients were randomly assigned to receive either Lz (2.5 mg/day) (n = 15) or T (1 mg/kg/month) (n = 13) for 6 months.
PARTICIPANTS/MATERIALS, SETTING, METHODS
The 28 patients were at least 14 years of age, showed first signs of puberty, wanted medical attention for CDGP and were evaluated at 0, 3, 6 and 12 months of visits. AMH levels were measured with an electrochemiluminescence immunoassay and Lz levels with liquid chromatography coupled with tandem mass spectrometry.
MAIN RESULTS AND THE ROLE OF CHANCE
AMH levels decreased in both treatment groups during the 12-month follow-up (P |
| doi_str_mv | 10.1093/humrep/dez231 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7048712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/humrep/dez231</oup_id><sourcerecordid>2343040721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-3497c9c07247cc962799f0367d15e8ad3b50c5ee6a75a4c36ccfa8def26f775d3</originalsourceid><addsrcrecordid>eNqFkb1uFDEUhS0EIkugTItcphninxl7pokURSEgBdFAbXntO1lHHnuxPVltXoFXouPF4mhCAhWVr3SPv3OuDkJHlHygZOAnm3lKsD2xcMc4fYFWtBWkYbwjL9GKMNE3lAp6gN7kfENIHXvxGh1wOnQ953KFfp6F4povv395D8npgDcxTTEA1sFiDyXFu-ihTrfgM3YBr-M-450rG2xiyMWVubgYtMcWvN7jOOLrFHd1_QDYzmtIZY9LAl3ALv-eqTHhArnEXCBVz7fo1ah9hneP7yH6_vHi2_mn5urr5efzs6vGtIyUhreDNIMhkrXSmEEwOQwj4UJa2kGvLV93xHQAQstOt4YLY0bdWxiZGKXsLD9Epwu3xpvAGgglaa-2yU067VXUTv27CW6jruOtkqTtJWUVcPwISPHHXC9Qk8sGvNcB4pwV4y0nbQ1Iq7RZpCbFnBOMTzaUqIcC1VKgWgqs-vd_Z3tS_2ns2TvO2_-w7gEBuq1F</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2343040721</pqid></control><display><type>article</type><title>Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone</title><source>Oxford Journals Online</source><creator>Kohva, E ; Varimo, T ; Huopio, H ; Tenhola, S ; Voutilainen, R ; Toppari, J ; Miettinen, P J ; Vaaralahti, K ; Viinamäki, J ; Backman, J T ; Hero, M ; Raivio, T</creator><creatorcontrib>Kohva, E ; Varimo, T ; Huopio, H ; Tenhola, S ; Voutilainen, R ; Toppari, J ; Miettinen, P J ; Vaaralahti, K ; Viinamäki, J ; Backman, J T ; Hero, M ; Raivio, T</creatorcontrib><description>Abstract
STUDY QUESTION
Does treatment of constitutional delay of growth and puberty (CDGP) in boys with aromatase inhibitor letrozole (Lz) or conventional low-dose testosterone (T) have differing effects on developing seminiferous epithelium?
SUMMARY ANSWER
Anti-Müllerian hormone (AMH) declined similarly in both treatment groups, and the two Sertoli cell-derived markers (AMH and inhibin B (iB)) exhibited differing responses to changes in gonadotrophin milieu.
WHAT IS KNOWN ALREADY
Boys with CDGP may benefit from puberty-inducing medication. Peroral Lz activates gonadotrophin secretion, whereas intramuscular low-dose T may transiently suppress gonadotrophins and iB.
STUDY DESIGN, SIZE, DURATION
Sera of 28 boys with CDGP who participated in a randomised, controlled, open-label trial at four paediatric centres in Finland between August 2013 and January 2017 were analysed. The patients were randomly assigned to receive either Lz (2.5 mg/day) (n = 15) or T (1 mg/kg/month) (n = 13) for 6 months.
PARTICIPANTS/MATERIALS, SETTING, METHODS
The 28 patients were at least 14 years of age, showed first signs of puberty, wanted medical attention for CDGP and were evaluated at 0, 3, 6 and 12 months of visits. AMH levels were measured with an electrochemiluminescence immunoassay and Lz levels with liquid chromatography coupled with tandem mass spectrometry.
MAIN RESULTS AND THE ROLE OF CHANCE
AMH levels decreased in both treatment groups during the 12-month follow-up (P < 0.0001). Between 0 and 3 months, the changes in gonadotrophin levels (increase in the Lz group, decrease in the T group) correlated strongly with the changes in levels of iB (FSH vs iB, r = 0.55, P = 0.002; LH vs iB, r = 0.72, P < 0.0001), but not with the changes in AMH (P = NS). At 12 months, AMH levels did not differ between the groups (P = NS). Serum Lz levels (range, 124–1262 nmol/L) were largely explained by the Lz dose per weight (at 3 months r = 0.62, P = 0.01; at 6 months r = 0.52, P = 0.05). Lz levels did not associate with changes in indices of hypothalamic-pituitary-gonadal axis activity or Sertoli cell markers (in all, P = NS).
LIMITATIONS, REASONS FOR CAUTION
The original trial was not blinded for practical reasons and included a limited number of participants.
WIDER IMPLICATIONS OF THE FINDINGS
In early puberty, treatment-induced gonadotrophin stimulus was unable to counteract the androgen-mediated decrease in AMH, while changes in iB levels were associated with changes in gonadotrophin levels. AMH decreased similarly in both groups during the treatment, reassuring safety of developing seminiferous epithelium in both treatment approaches. Since a fixed dose of Lz induced variable serum Lz levels with a desired puberty-promoting effect in all boys, more research is needed to aim at a minimal efficient dose per weight.
STUDY FUNDING/COMPETING INTEREST(S)
This study was supported by the Academy of Finland, the Foundation for Pediatric Research, the Emil Aaltonen Foundation, Sigrid Juselius Foundation and Helsinki University Hospital Research Funds. The authors have nothing to disclose.
TRIAL REGISTRATION NUMBER
NCT01797718</description><identifier>ISSN: 0268-1161</identifier><identifier>EISSN: 1460-2350</identifier><identifier>DOI: 10.1093/humrep/dez231</identifier><identifier>PMID: 31958337</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adolescent ; Andrology ; Anti-Mullerian Hormone - blood ; Biomarkers - blood ; Child ; Female ; Finland ; Growth Disorders - blood ; Growth Disorders - drug therapy ; Humans ; Hypogonadism - blood ; Inhibins - blood ; Letrozole - administration & dosage ; Letrozole - blood ; Letrozole - therapeutic use ; Male ; Original ; Puberty, Delayed - blood ; Puberty, Delayed - drug therapy ; Testosterone - administration & dosage ; Testosterone - therapeutic use</subject><ispartof>Human reproduction (Oxford), 2020-02, Vol.35 (2), p.257-264</ispartof><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. 2020</rights><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-3497c9c07247cc962799f0367d15e8ad3b50c5ee6a75a4c36ccfa8def26f775d3</citedby><cites>FETCH-LOGICAL-c420t-3497c9c07247cc962799f0367d15e8ad3b50c5ee6a75a4c36ccfa8def26f775d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31958337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kohva, E</creatorcontrib><creatorcontrib>Varimo, T</creatorcontrib><creatorcontrib>Huopio, H</creatorcontrib><creatorcontrib>Tenhola, S</creatorcontrib><creatorcontrib>Voutilainen, R</creatorcontrib><creatorcontrib>Toppari, J</creatorcontrib><creatorcontrib>Miettinen, P J</creatorcontrib><creatorcontrib>Vaaralahti, K</creatorcontrib><creatorcontrib>Viinamäki, J</creatorcontrib><creatorcontrib>Backman, J T</creatorcontrib><creatorcontrib>Hero, M</creatorcontrib><creatorcontrib>Raivio, T</creatorcontrib><title>Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone</title><title>Human reproduction (Oxford)</title><addtitle>Hum Reprod</addtitle><description>Abstract
STUDY QUESTION
Does treatment of constitutional delay of growth and puberty (CDGP) in boys with aromatase inhibitor letrozole (Lz) or conventional low-dose testosterone (T) have differing effects on developing seminiferous epithelium?
SUMMARY ANSWER
Anti-Müllerian hormone (AMH) declined similarly in both treatment groups, and the two Sertoli cell-derived markers (AMH and inhibin B (iB)) exhibited differing responses to changes in gonadotrophin milieu.
WHAT IS KNOWN ALREADY
Boys with CDGP may benefit from puberty-inducing medication. Peroral Lz activates gonadotrophin secretion, whereas intramuscular low-dose T may transiently suppress gonadotrophins and iB.
STUDY DESIGN, SIZE, DURATION
Sera of 28 boys with CDGP who participated in a randomised, controlled, open-label trial at four paediatric centres in Finland between August 2013 and January 2017 were analysed. The patients were randomly assigned to receive either Lz (2.5 mg/day) (n = 15) or T (1 mg/kg/month) (n = 13) for 6 months.
PARTICIPANTS/MATERIALS, SETTING, METHODS
The 28 patients were at least 14 years of age, showed first signs of puberty, wanted medical attention for CDGP and were evaluated at 0, 3, 6 and 12 months of visits. AMH levels were measured with an electrochemiluminescence immunoassay and Lz levels with liquid chromatography coupled with tandem mass spectrometry.
MAIN RESULTS AND THE ROLE OF CHANCE
AMH levels decreased in both treatment groups during the 12-month follow-up (P < 0.0001). Between 0 and 3 months, the changes in gonadotrophin levels (increase in the Lz group, decrease in the T group) correlated strongly with the changes in levels of iB (FSH vs iB, r = 0.55, P = 0.002; LH vs iB, r = 0.72, P < 0.0001), but not with the changes in AMH (P = NS). At 12 months, AMH levels did not differ between the groups (P = NS). Serum Lz levels (range, 124–1262 nmol/L) were largely explained by the Lz dose per weight (at 3 months r = 0.62, P = 0.01; at 6 months r = 0.52, P = 0.05). Lz levels did not associate with changes in indices of hypothalamic-pituitary-gonadal axis activity or Sertoli cell markers (in all, P = NS).
LIMITATIONS, REASONS FOR CAUTION
The original trial was not blinded for practical reasons and included a limited number of participants.
WIDER IMPLICATIONS OF THE FINDINGS
In early puberty, treatment-induced gonadotrophin stimulus was unable to counteract the androgen-mediated decrease in AMH, while changes in iB levels were associated with changes in gonadotrophin levels. AMH decreased similarly in both groups during the treatment, reassuring safety of developing seminiferous epithelium in both treatment approaches. Since a fixed dose of Lz induced variable serum Lz levels with a desired puberty-promoting effect in all boys, more research is needed to aim at a minimal efficient dose per weight.
STUDY FUNDING/COMPETING INTEREST(S)
This study was supported by the Academy of Finland, the Foundation for Pediatric Research, the Emil Aaltonen Foundation, Sigrid Juselius Foundation and Helsinki University Hospital Research Funds. The authors have nothing to disclose.
TRIAL REGISTRATION NUMBER
NCT01797718</description><subject>Adolescent</subject><subject>Andrology</subject><subject>Anti-Mullerian Hormone - blood</subject><subject>Biomarkers - blood</subject><subject>Child</subject><subject>Female</subject><subject>Finland</subject><subject>Growth Disorders - blood</subject><subject>Growth Disorders - drug therapy</subject><subject>Humans</subject><subject>Hypogonadism - blood</subject><subject>Inhibins - blood</subject><subject>Letrozole - administration & dosage</subject><subject>Letrozole - blood</subject><subject>Letrozole - therapeutic use</subject><subject>Male</subject><subject>Original</subject><subject>Puberty, Delayed - blood</subject><subject>Puberty, Delayed - drug therapy</subject><subject>Testosterone - administration & dosage</subject><subject>Testosterone - therapeutic use</subject><issn>0268-1161</issn><issn>1460-2350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqFkb1uFDEUhS0EIkugTItcphninxl7pokURSEgBdFAbXntO1lHHnuxPVltXoFXouPF4mhCAhWVr3SPv3OuDkJHlHygZOAnm3lKsD2xcMc4fYFWtBWkYbwjL9GKMNE3lAp6gN7kfENIHXvxGh1wOnQ953KFfp6F4povv395D8npgDcxTTEA1sFiDyXFu-ihTrfgM3YBr-M-450rG2xiyMWVubgYtMcWvN7jOOLrFHd1_QDYzmtIZY9LAl3ALv-eqTHhArnEXCBVz7fo1ah9hneP7yH6_vHi2_mn5urr5efzs6vGtIyUhreDNIMhkrXSmEEwOQwj4UJa2kGvLV93xHQAQstOt4YLY0bdWxiZGKXsLD9Epwu3xpvAGgglaa-2yU067VXUTv27CW6jruOtkqTtJWUVcPwISPHHXC9Qk8sGvNcB4pwV4y0nbQ1Iq7RZpCbFnBOMTzaUqIcC1VKgWgqs-vd_Z3tS_2ns2TvO2_-w7gEBuq1F</recordid><startdate>20200229</startdate><enddate>20200229</enddate><creator>Kohva, E</creator><creator>Varimo, T</creator><creator>Huopio, H</creator><creator>Tenhola, S</creator><creator>Voutilainen, R</creator><creator>Toppari, J</creator><creator>Miettinen, P J</creator><creator>Vaaralahti, K</creator><creator>Viinamäki, J</creator><creator>Backman, J T</creator><creator>Hero, M</creator><creator>Raivio, T</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200229</creationdate><title>Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone</title><author>Kohva, E ; Varimo, T ; Huopio, H ; Tenhola, S ; Voutilainen, R ; Toppari, J ; Miettinen, P J ; Vaaralahti, K ; Viinamäki, J ; Backman, J T ; Hero, M ; Raivio, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-3497c9c07247cc962799f0367d15e8ad3b50c5ee6a75a4c36ccfa8def26f775d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Andrology</topic><topic>Anti-Mullerian Hormone - blood</topic><topic>Biomarkers - blood</topic><topic>Child</topic><topic>Female</topic><topic>Finland</topic><topic>Growth Disorders - blood</topic><topic>Growth Disorders - drug therapy</topic><topic>Humans</topic><topic>Hypogonadism - blood</topic><topic>Inhibins - blood</topic><topic>Letrozole - administration & dosage</topic><topic>Letrozole - blood</topic><topic>Letrozole - therapeutic use</topic><topic>Male</topic><topic>Original</topic><topic>Puberty, Delayed - blood</topic><topic>Puberty, Delayed - drug therapy</topic><topic>Testosterone - administration & dosage</topic><topic>Testosterone - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kohva, E</creatorcontrib><creatorcontrib>Varimo, T</creatorcontrib><creatorcontrib>Huopio, H</creatorcontrib><creatorcontrib>Tenhola, S</creatorcontrib><creatorcontrib>Voutilainen, R</creatorcontrib><creatorcontrib>Toppari, J</creatorcontrib><creatorcontrib>Miettinen, P J</creatorcontrib><creatorcontrib>Vaaralahti, K</creatorcontrib><creatorcontrib>Viinamäki, J</creatorcontrib><creatorcontrib>Backman, J T</creatorcontrib><creatorcontrib>Hero, M</creatorcontrib><creatorcontrib>Raivio, T</creatorcontrib><collection>Oxford University Press Journals Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Human reproduction (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kohva, E</au><au>Varimo, T</au><au>Huopio, H</au><au>Tenhola, S</au><au>Voutilainen, R</au><au>Toppari, J</au><au>Miettinen, P J</au><au>Vaaralahti, K</au><au>Viinamäki, J</au><au>Backman, J T</au><au>Hero, M</au><au>Raivio, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone</atitle><jtitle>Human reproduction (Oxford)</jtitle><addtitle>Hum Reprod</addtitle><date>2020-02-29</date><risdate>2020</risdate><volume>35</volume><issue>2</issue><spage>257</spage><epage>264</epage><pages>257-264</pages><issn>0268-1161</issn><eissn>1460-2350</eissn><abstract>Abstract
STUDY QUESTION
Does treatment of constitutional delay of growth and puberty (CDGP) in boys with aromatase inhibitor letrozole (Lz) or conventional low-dose testosterone (T) have differing effects on developing seminiferous epithelium?
SUMMARY ANSWER
Anti-Müllerian hormone (AMH) declined similarly in both treatment groups, and the two Sertoli cell-derived markers (AMH and inhibin B (iB)) exhibited differing responses to changes in gonadotrophin milieu.
WHAT IS KNOWN ALREADY
Boys with CDGP may benefit from puberty-inducing medication. Peroral Lz activates gonadotrophin secretion, whereas intramuscular low-dose T may transiently suppress gonadotrophins and iB.
STUDY DESIGN, SIZE, DURATION
Sera of 28 boys with CDGP who participated in a randomised, controlled, open-label trial at four paediatric centres in Finland between August 2013 and January 2017 were analysed. The patients were randomly assigned to receive either Lz (2.5 mg/day) (n = 15) or T (1 mg/kg/month) (n = 13) for 6 months.
PARTICIPANTS/MATERIALS, SETTING, METHODS
The 28 patients were at least 14 years of age, showed first signs of puberty, wanted medical attention for CDGP and were evaluated at 0, 3, 6 and 12 months of visits. AMH levels were measured with an electrochemiluminescence immunoassay and Lz levels with liquid chromatography coupled with tandem mass spectrometry.
MAIN RESULTS AND THE ROLE OF CHANCE
AMH levels decreased in both treatment groups during the 12-month follow-up (P < 0.0001). Between 0 and 3 months, the changes in gonadotrophin levels (increase in the Lz group, decrease in the T group) correlated strongly with the changes in levels of iB (FSH vs iB, r = 0.55, P = 0.002; LH vs iB, r = 0.72, P < 0.0001), but not with the changes in AMH (P = NS). At 12 months, AMH levels did not differ between the groups (P = NS). Serum Lz levels (range, 124–1262 nmol/L) were largely explained by the Lz dose per weight (at 3 months r = 0.62, P = 0.01; at 6 months r = 0.52, P = 0.05). Lz levels did not associate with changes in indices of hypothalamic-pituitary-gonadal axis activity or Sertoli cell markers (in all, P = NS).
LIMITATIONS, REASONS FOR CAUTION
The original trial was not blinded for practical reasons and included a limited number of participants.
WIDER IMPLICATIONS OF THE FINDINGS
In early puberty, treatment-induced gonadotrophin stimulus was unable to counteract the androgen-mediated decrease in AMH, while changes in iB levels were associated with changes in gonadotrophin levels. AMH decreased similarly in both groups during the treatment, reassuring safety of developing seminiferous epithelium in both treatment approaches. Since a fixed dose of Lz induced variable serum Lz levels with a desired puberty-promoting effect in all boys, more research is needed to aim at a minimal efficient dose per weight.
STUDY FUNDING/COMPETING INTEREST(S)
This study was supported by the Academy of Finland, the Foundation for Pediatric Research, the Emil Aaltonen Foundation, Sigrid Juselius Foundation and Helsinki University Hospital Research Funds. The authors have nothing to disclose.
TRIAL REGISTRATION NUMBER
NCT01797718</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>31958337</pmid><doi>10.1093/humrep/dez231</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-1161 |
| ispartof | Human reproduction (Oxford), 2020-02, Vol.35 (2), p.257-264 |
| issn | 0268-1161 1460-2350 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7048712 |
| source | Oxford Journals Online |
| subjects | Adolescent Andrology Anti-Mullerian Hormone - blood Biomarkers - blood Child Female Finland Growth Disorders - blood Growth Disorders - drug therapy Humans Hypogonadism - blood Inhibins - blood Letrozole - administration & dosage Letrozole - blood Letrozole - therapeutic use Male Original Puberty, Delayed - blood Puberty, Delayed - drug therapy Testosterone - administration & dosage Testosterone - therapeutic use |
| title | Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A13%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-M%C3%BCllerian%20hormone%20and%20letrozole%20levels%20in%20boys%20with%20constitutional%20delay%20of%20growth%20and%20puberty%20treated%20with%20letrozole%20or%20testosterone&rft.jtitle=Human%20reproduction%20(Oxford)&rft.au=Kohva,%20E&rft.date=2020-02-29&rft.volume=35&rft.issue=2&rft.spage=257&rft.epage=264&rft.pages=257-264&rft.issn=0268-1161&rft.eissn=1460-2350&rft_id=info:doi/10.1093/humrep/dez231&rft_dat=%3Cproquest_pubme%3E2343040721%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-3497c9c07247cc962799f0367d15e8ad3b50c5ee6a75a4c36ccfa8def26f775d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2343040721&rft_id=info:pmid/31958337&rft_oup_id=10.1093/humrep/dez231&rfr_iscdi=true |